Replies to post #2140 on Idenix Pharmaceuticals (IDIX)

[keitern]

Thanks Dew, for that update; crazy growth and no reason, I trust, that Tyzeka/Sebivo cannot share in that ramp up.

OT: From all I can read in the filings, I can't help but think TMTA is a buy at these levels. Am I missing something obvious. In connection with that question would be the wild card of lawyers cut/fees.

[DewDiligence]

69% of Baraclude sales in 3Q07 were outside the US. This is consistent with statements made by IDIX management that the Tyzeka uptake has been faster outside the US. However, Tyzeka has already been launched in only two of the major European countries (UK and Germany), so it is still early days.

[DewDiligence]

4Q07 Baraclude sales: $99M, +175% (!) vs 4Q06 and +38% vs 3Q07.

This is a $400M annualized rate.

$70M of the $99M came from outside the US; this number was boosted to some degree by currency.

http://biz.yahoo.com/prnews/080131/nyth043.html

Baraclude has now surpassed Hepsera as the leading HBV drug in worldwide sales. As noted in #msg-26221188, Hepsera sales have plateaued and can be expected to become less and less of a factor in the HBV market, especially when Viread is launched later this year.